| Dr Jose Perez Martell, MD | |
|
189 Storrs Rd, Mansfield Center, CT 06250-1683 | |
| (860) 456-1311 | |
| Not Available |
| Full Name | Dr Jose Perez Martell |
|---|---|
| Gender | Male |
| Speciality | Psychiatry |
| Experience | 5 Years |
| Location | 189 Storrs Rd, Mansfield Center, Connecticut |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1821653247 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084A0401X | Psychiatry & Neurology - Addiction Medicine | 73418 (Connecticut) | Secondary |
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 73418 (Connecticut) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Natchaug Hospital, Inc | 5395648737 | 16 |
News Archive
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 6 days ago
| Entity Name | Windham Community Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023191467 PECOS PAC ID: 2961309059 Enrollment ID: O20031217000231 |
News Archive
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 6 days ago
| Entity Name | Natchaug Hospital, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295811321 PECOS PAC ID: 5395648737 Enrollment ID: O20040202000008 |
News Archive
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 6 days ago
| Entity Name | The William W Backus Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467517235 PECOS PAC ID: 0749170645 Enrollment ID: O20040316000739 |
News Archive
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 6 days ago
| Entity Name | State Of Connecticut |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245256247 PECOS PAC ID: 8022915677 Enrollment ID: O20040319000535 |
News Archive
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jose Perez Martell, MD 300 George St, New Haven, CT 06511-6624 Ph: () - | Dr Jose Perez Martell, MD 189 Storrs Rd, Mansfield Center, CT 06250-1683 Ph: (860) 456-1311 |
News Archive
A majority of healthcare studies are conducted using a randomized control trial (RCT). These trials randomly assign participants into groups who either receive or do not receive treatment. However, until the mid-1990s, some of these studies were falling victim to inadequate reporting, thereby causing confusing and potentially biased results.
N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration. N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR), has the potential to be an important new treatment for acute exacerbations of asthma, chronic obstructive pulmonary disease (COPD) and inflammatory bowel disease (IBD).
The life expectancy of people diagnosed with type 1 diabetes dramatically increased during the course of a 30-year, long-term prospective study, according to a University of Pittsburgh Graduate School of Public Health study being presented at the 71st Scientific Sessions of the American Diabetes Association.
Palatin Technologies, Inc. (NYSE Amex: PTN) today announced results for its fourth quarter and fiscal year ended June 30, 2009. For the year ended June 30, 2009, total revenues were $11.4 million, compared to $11.5 million for year ended June 30, 2008. Palatin's net loss for the year ended June 30, 2009 was $4.8 million, or $(0.06) per basic and diluted share, compared to a net loss of $14.4 million, or $(0.17) per basic and diluted share, for the year ended June 30, 2008.
› Verified 6 days ago
Dr. Craig Martin, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 189 Storrs Rd, Mansfield Center, CT 06250 Phone: 860-456-1311 Fax: 860-450-0165 | |
Dr. Vanessa Rose Green, D.O. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 189 Storrs Rd, Mansfield Center, CT 06250 Phone: 860-456-1311 | |
Deborah A Weidner, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 189 Storrs Rd, Natchaug Hospital, Mansfield Center, CT 06250 Phone: 860-456-1311 | |
Paul E. Weigle, M.D. Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 189 Storrs Rd, Mansfield Center, CT 06250 Phone: 860-456-1311 Fax: 860-423-5922 | |
Gengyun Wen, Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 189 Storrs Rd, Natchaug Hospital, Mansfield Center, CT 06250 Phone: 860-456-1311 | |
Dr. Sarah Jane De Asis Vargas, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 140 N Frontage Rd, Mansfield Center, CT 06250 Phone: 860-774-2020 | |
Dr. Stanley Paul Dugan, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 9 Overlook Dr, Mansfield Center, CT 06250 Phone: 860-456-0257 |